碳酸镧咀嚼片联合碳酸司维拉姆片治疗肾功能不全失代偿期高磷血症的临床研究  

Clinical trial of lanthanum carbonate chewable tablets combined with sevelamer carbonate tablets in the treatment of renal insufficiency decompensation complicated with hyperphosphatemia

作　　者：郑慧[1] 刘智楠[1] 郭向辉 张丹丹[1] ZHENG Hui;LIU Zhi-nan;GUO Xiang-hui;ZHANG Dan-dan(Department of Nephrology,Tangshan City Workers ’ Hospital, Tangshan 063000,Hebei Province,China)

机构地区：[1]唐山市工人医院肾内科

出　　处：《中国临床药理学杂志》2019年第14期1422-1424,共3页The Chinese Journal of Clinical Pharmacology

基　　金：河北省医学科学研究重点课题计划资助项目(ZD20140173)

摘　　要：目的观察碳酸镧咀嚼片联合碳酸司维拉姆片治疗肾功能不全失代偿期高磷血症的临床疗效及安全性。方法将90例肾功能不全失代偿期高磷血症患者随机分为对照组和试验组,每组45例。对照组予以碳酸镧咀嚼片每次500mg,tid,口服。试验组在对照组治疗的基础上,予以碳酸司维拉姆片每次0. 8 g,tid,口服。2组患者均治疗3个月。比较2组患者的临床疗效,血磷和肾功能,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为93. 33%(42例/45例)和68. 89%(31例/45例),差异有统计学意义(P <0. 05)。治疗后,试验组和对照组的血磷分别为(1. 12±0. 17)和(1. 43±0. 19) mmol·L^-1,血清肌酸酐分别为(209. 56±39. 52)和(278. 58±34. 29)μmol·L^-1,尿素氮分别为(11. 41±3. 62)和(15. 98±5. 66)mmol·L^-1,差异均有统计学意义(均P <0. 05)。试验组发生的药物不良反应有便秘和恶心,对照组发生的药物不良反应有便秘、恶心、腹痛和腹胀。试验组和对照组的总药物不良反应发生率分别为6. 67%和22. 22%,差异有统计学意义(P <0. 05)。结论碳酸镧咀嚼片联合碳酸司维拉姆片治疗肾功能不全失代偿期高磷血症的临床疗效显著,且不增加药物不良反应的发生率。Objective To observe the clinical efficacy and safety of lanthanum carbonate chewable tablets combined with sevelamer carbonate tablets in the treatment of renal insufficiency decompensation complicated with hyperphosphatemia. Methods A total of 90 patients with renal insufficiency decompensation complicated with hyperphosphatemia were randomly divided into control and treatment groups with 45 cases per group. Control group was given lanthanum carbonate chewable tablets500 mg per time, tid, orally. Treatment group received sevelamer carbonate tablets 0. 8 g per time,tid,orally,on the basis of control group. Two groups were treated for 3 months. The clinical efficacy,serum phosphorus,renal function and adverse drug reactions were compared between two groups. Results After treatment,the total effective rates of treatment and control groups were 93. 33%( 42 cases/45 cases) and68. 89%( 31 cases/45 cases) with significant difference( P < 0. 05).After treatment,the main indexes of treatment and control groups were compared: serum phosphorus were( 1. 12 ± 0. 17) and( 1. 43 ± 0. 19) mmol·L^-1, serum creatinine were( 209. 56 ± 39. 52) and( 278. 58 ± 34. 29)μmol·L^-1,urea nitrogen were( 11. 41 ± 3. 62) and( 15. 98 ± 5. 66)mmol·L^-1,the differences were statistically significant( all P < 0. 05). The adverse drug reactions of treatment group were constipation and nausea,which in control group were constipation,nausea,abdominal pain and abdominal distension. The total incidences of adverse drug reactions of treatment and control groups were 6. 67% and 22. 22% with significant difference( P < 0. 05). Conclusion Lanthanum carbonate chewable tablets combined with sevelamer carbonate tablets have a definitive clinical efficacy in the treatment of renal insufficiency decompensation complicated with hyperphosphatemia,without increasing the incidence of adverse drug reactions.

关 键 词：碳酸镧咀嚼片 司维拉姆片 肾功能不全失代偿期高磷血症 安全性评价 

分 类 号：R97[医药卫生—药品]